Presley Gerber’s Death Sparks Discussion on Addiction Recovery and Risks

Presley Gerber, son of Cindy Crawford and Rande Gerber, passed away at 27 while at a California rehabilitation facility. His death has brought to light issues surrounding overdose risks, withdrawal complications, and the challenges associated with addiction recovery.

The Los Angeles County Medical Examiner’s Office confirmed Gerber’s death, though the exact cause remains unverified. Audio recordings indicate police responded to a cardiac arrest call at the facility, with suggestions of a potential overdose. Further testing is underway to determine the cause.

Addiction and Recovery Risks

Nicholas Kardaris, Ph.D., highlights the complexities involved in rehabilitation and warns against assuming causes. While Gerber struggled with substance use and mental health, caution is needed before drawing conclusions about events at a rehab facility. Acute medical issues, unknown conditions, or medication-related complications may play a role.

Cardiac events can be triggered by certain medications, especially if underlying health issues exist. Kardaris underscores that rehab is not a cure for addiction. Facilities strive for a controlled environment but can’t eliminate all risks like withdrawal, relapse, or medical complications.

The Risks of Withdrawal

Withdrawal dangers vary based on the substance and physical dependence level. Benzodiazepines, such as Valium and Xanax, pose significant risks, with potential seizures and serious complications. Opioid withdrawal is uncomfortable but not usually fatal.

Benzodiazepine withdrawal can result in seizures, delirium, and other life-threatening issues. Disclosing concurrent drug use is critical for managing withdrawal safely. Kardaris emphasizes post-rehab overdose risks, as tolerance decreases when abstaining, raising danger upon relapse.

Controversy Surrounding Ibogaine

Gerber mentioned undergoing ibogaine treatment on social media. Kardaris points out ibogaine’s lack of FDA approval for medical use in the U.S. Despite research on its potential for opioid disorder treatment, its safety and efficacy remain uncertain.

Psychoactive substances like ketamine, ayahuasca, and ibogaine draw interest without full regulatory oversight. These treatments lack FDA approval in the U.S.; evidence and oversight vary widely.

Kardaris advised researching and verifying treatment center credentials and protocols, including medical professional involvement and emergency procedures. Families should ensure centers are licensed and reputable.

Overall, addiction recovery remains a challenging process with many associated risks. Critical understanding and evaluation of treatment options are essential for families dealing with addiction.